Prostate Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Q4 2010

Report Summary

GlobalData's pharmaceutical report, “Prostate Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Q4 2010” is an essential source of information and analysis on the global prostate cancer therapeutics market. The report provides comprehensive information on prostate cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global prostate cancer therapeutics market. It analyses the treatment usage patterns in the global prostate cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global prostate cancer sector. It quantifies the unmet need in the global prostate cancer therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:

• An overview of prostate cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
• Annualized global prostate cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.
• Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France Japan and BRIC countries that include Brazil, Russia, India and China
• Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
• Competitor assessment including drug launch analysis and drug sales forecasts.
• Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities, product positioning and drug sales forecast.
• Analysis of unmet need in the market and target product profile including opportunity for target product.
• Technology trends analytic framework to assess strength of pipeline.
• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, tyrosine kinase inhibitor, angiogenesis inhibitors and others.
• An overview of the most promising drugs’ including clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forcasts to 2020.
• Analysis of the current and future market competition in the global Prostate Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Sanofi-aventis, Pfizer, Inc., AstraZeneca PLC, Bristol-Myers Squibb, Medivation, Takeda Pharmaceuticals and Dendreon Corporation.
• Analysis of licensing agreements during 2004-2010 in the prostate cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.
• Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
• Direct quotes from key opinion leaders (KOL) or physicians in the prostate cancer therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

• Develop business strategies and perform superior market quantification analysis by
• Understanding the trends shaping and driving the global prostate cancer therapeutics market.
• Understanding treatment preferences of physicians in disease state and across treatment flow.
• Accessing market sizing, forecasts and quantified growth opportunities in the global prostate cancer therapeutics market till 2020.
• Quantifying patient population in the global prostate cancer market to better design product pricing & launch plans.
• Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
• Performing benchmarking analysis and growth opportunities against currently marketed products
• Identifying market entry points based on safety, efficacy, and pricing parameters.
• Assessing competitiveness of products in market by understanding the strength and weakness of current competition.
• Develop and design your in-licensing and out-licensing strategies by
• Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
• Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
• Track drug sales in the global prostate cancer therapeutics market from 2001 to 2020
• Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
• What’s the next big thing in the global prostate cancer therapeutics market landscape? Identify, understand and capitalize.

Table of Contents

1 Table of contents
1.1 List of Tables
1.2 List of Figures

2 Disease Overview
2.1 Overview
2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System
2.1.2 Jewett-Whitmore system
2.2 Epidemiology
2.3 Etiology
2.4 Symptoms
2.4.1 Localized or Locally Advanced Prostate Cancer
2.4.2 Metastatic Prostate Cancer
2.5 Diagnosis
2.5.1 Digital Rectal Examination
2.5.2 Prostate Specific Antigen Test
2.5.3 Transrectal Ultrasound
2.5.4 Prostate Biopsy
2.6 Pathology
2.6.1 Grading
2.7 Treatment
2.7.1 Watchful Waiting
2.7.2 Radiation therapy
2.7.3 Surgery
2.7.4 Hormone therapy
2.7.5 Chemotherapy Options
2.7.6 Other Treatments Being Studied
2.8 Treatment Guidelines

3 Market Characterization
3.1 Global
3.1.1 Market Size
3.1.2 Drivers & Barriers
3.1.3 Forecasts
3.1.4 Drug Sales
3.2 The US
3.2.1 Market Size
3.2.2 Drivers and Restraints
3.2.3 Forecasts
3.2.4 Drug Sales
3.2.5 Pricing & Reimbursements
3.3 The UK
3.3.1 Market Size
3.3.2 Drivers and Barriers
3.3.3 Impact on the Market
3.3.4 Forecasts
3.3.5 Drug Sales
3.3.6 Pricing and Reimbursements
3.4 Germany
3.4.1 Market Size
3.4.2 Drivers and Barriers
3.4.3 Impact on the Market
3.4.4 Forecasts
3.4.5 Drug Sales
3.4.6 Pricing & Reimbursements
3.5 France
3.5.1 Market Size
3.5.2 Drivers & Barriers
3.5.3 Impact on the Market
3.5.4 Forecasts
3.5.5 Drug Sales
3.5.6 Pricing & Reimbursements
3.6 Italy
3.6.1 Market Size
3.6.2 Drivers & Barriers
3.6.3 Impact on the Market
3.6.4 Forecasts
3.6.5 Drug Sales
3.6.6 Pricing and Reimbursements
3.7 Spain
3.7.1 Market Size
3.7.2 Drivers and Barriers
3.7.3 Impact on the Market
3.7.4 Forecasts
3.7.5 Drug Sales
3.7.6 Pricing and Reimbursements
3.8 Japan
3.8.1 Market Size
3.8.2 Drivers and Barriers
3.8.3 Impact on the Market
3.8.4 Forecasts
3.8.5 Future Impact
3.8.6 Drug Sales
3.8.7 Pricing & Reimbursements
3.9 Brazil
3.9.1 Market Size
3.9.2 Drivers and Restraints
3.9.3 Impact on the Market
3.9.4 Forecasts
3.9.5 Future Impact
3.10 Russia
3.10.1 Market Size
3.10.2 Drivers and Restraints
3.10.3 Impact on the Market
3.10.4 Forecasts
3.10.5 Future Impact
3.11 India
3.11.1 Market Size (2001-2009)
3.11.2 Drivers and Restraints
3.11.3 Impact on the Market
3.11.4 Forecasts (2010-2020)
3.11.5 Future Impact
3.12 China
3.12.1 Market Size (2001-2009)
3.12.2 Drivers and Restraints
3.12.3 Impact on the Market
3.12.4 Forecasts (2010-2020)
3.12.5 Future Impact
3.13 Key Takeaway

4 Competitor Assessment
4.1 Strategic Competitor Assessment
4.1.1 Overview
4.1.2 Benchmarking
4.1.3 Current Competitor Assessment
4.2 Launch Analysis and Sales Forecasts
4.3 Product Profiles
4.3.1 Taxotere (docetaxel)
4.3.2 Casodex (Bicalutamide)
4.3.3 Zoladex (Goserelin)
4.3.4 Provenge (sipuleucel-T)
4.3.5 Jevtana (cabazitaxel)
4.3.6 Eligard (leuprolide acetate)
4.3.7 Lupron (Leuprolide acetate)
4.3.8 Prostap (leuprolide acetate)
4.3.9 Firmagon (degarelix)
4.3.10 Vantas (Histrelin)
4.3.11 Novantrone (Mitoxantrone hydrochloride)
4.3.12 Emcyt (estramustine)
4.3.13 Trelstar (triptorelin)
4.3.14 Eulexin
4.3.15 Delestrogen
4.3.16 Gynodiol
4.3.17 Estrace tablet
4.3.18 Tace
4.3.19 Nilandrone
4.3.20 Premarin
4.3.21 Sales Forecast for Trelstar, Decapeptyl, Gonapeptyl, Flutamide, Estradiol

5 Pipeline Assessment
5.1 Overview
5.2 Pipeline Analysis by Phase of Development
5.3 Pipeline by Mechanism of Action
5.4 Strategic Pipeline Assessment
5.4.1 Technology Trends Analytical Framework
5.5 Trends in Prostate Cancer Pipeline
5.5.1 More Clarity on the Origin of Prostate Cancer Will Help in Identifying Novel Targets for Prostate Cancer Drugs
5.5.2 Molecules with Novel Mechanism of Action Strengthening Prostate Cancer Pipeline
5.5.3 Failure of Key Molecules to Achieve Positive Results in Phase III Development
5.6 Partners in Research and Development
5.6.1 Licensing Agreements by Phase of Development
5.6.2 Licensing Agreements by Geography
5.6.3 Licensing Agreements: Technology Licensing Agreements in Prostate Cancer
5.7 Most Promising Drugs’ Profiles
5.7.1 Aflibercept (VEGF Trap)
5.7.2 Ipilimumab
5.7.3 Abiraterone Acetate (CB7630)
5.7.4 Zibotentan (ZD4054)
5.7.5 Sprycel (dasatinib)
5.7.6 MDV3100
5.8 Prostate Cancer Pipeline - Pre-clinical Phase
5.9 Prostate Cancer Pipeline - Phase I
5.10 Prostate Cancer Pipeline - Phase II
5.11 Prostate Cancer Pipeline - Phase III
5.12 Key Takeaway

6 Unmet Need and Target Product Profile
6.1 Unmet Need
6.1.1 Hormone-independent Metastatic Prostate Cancer Therapy
6.1.2 Hormone-dependent Metastatic Prostate Cancer Therapy
6.2 Opportunity for Target Product
6.3 Target Product Profile
6.3.1 Ideal Characteristics
6.3.2 Target Product Description
6.4 Key Takeaway

7 Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Market Impact Analysis
7.3 Future Market Scenario
7.4 Company Analysis
7.4.1 Market Leadership
7.4.2 Future Players in the Market
7.5 Key Takeaway

8 Company Profiles
8.1 Sanofi-aventis
8.1.1 Business Description
8.1.2 Financial Overview
8.1.3 SWOT Analysis
8.1.4 Oncology Focus
8.2 Pfizer Inc.
8.2.1 Business Description
8.2.2 Financial Overview
8.2.3 SWOT Analysis
8.2.4 Oncology Focus
8.3 AstraZeneca
8.3.1 Business Description
8.3.2 Financial Overview
8.3.3 SWOT Analysis
8.3.4 Oncology Focus
8.4 Bristol-Myers Squibb
8.4.1 Business Description
8.4.2 Financial Overview
8.4.3 SWOT Analysis
8.4.4 Oncology Focus
8.5 Medivation
8.5.1 Business Description
8.5.2 SWOT Analysis
8.5.3 Oncology Focus
8.6 Takeda Pharmaceuticals
8.6.1 Business Description
8.6.2 SWOT Analysis
8.7 Dendreon Corporation
8.7.1 Business Description
8.7.2 SWOT Analysis
8.8 Johnson and Johnson
8.8.1 Business Description
8.8.2 SWOT Analysis
8.8.3 Oncology Focus
8.9 Auron Healthcare GmbH
8.9.1 Business Description
8.10 Oncogenex Pharmaceuticals, Inc.
8.10.1 Business Description
8.11 Agennix AG
8.11.1 Business Description
8.12 GTx, Inc.
8.12.1 Business Description
8.13 GlaxoSmithKline plc.
8.13.1 Business Description
8.13.2 Financial Overview
8.13.3 SWOT Analysis
8.13.4 Oncology Focus

9 M&A Analysis
9.1 Key Highlights
9.2 Key Deals’ Analysis
9.2.1 Johnson & Johnson Acquires Cougar Biotechnology
9.2.2 Endo Pharmaceuticals Acquires Indevus Pharmaceuticals
9.2.3 Tolmar Holding Acquires QLT USA from QLT
9.2.4 Biomarin Pharmaceutical to Acquire Lead therapeutics
9.2.5 Isis Pharmaceuticals Reacquires Rights to Cancer Drug from Eli Lilly & Co.
9.2.6 Quest PharmaTech Acquires Late-stage Immunotherapeutic Antibody Pipeline from Paladin Labs
9.2.7 VaxOnco Acquires Rights to Onyvax-P Cell Vaccine From Onyvax
9.2.8 GPC Biotech Merges with Agennix
9.2.9 Eli Lilly Acquires ImClone
9.2.10 Sagent Pharmaceuticals Acquires Injectable Generic Drug Applications of Spectrum Pharmaceuticals
9.3 M&A Deals by Geography
9.4 M&A Deals by Deal Size

10 Expert Opinion
10.1 US
10.2 UK
10.3 Germany
10.4 France
10.5 Italy
10.6 Spain
10.7 Japan

11 Appendix
11.1 Market Definitions
11.2 Abbreviations
11.3 Research Methodology
11.3.1 Coverage
11.3.2 Secondary Research
11.3.3 Forecasting
11.3.4 Primary Research
11.3.5 Expert Panel validation
11.3.6 Contact Us
11.3.7 Disclaimer

1.2 List of Figures

Figure 1: Prostate Cancer Therapeutics Market, Global, Treatment Guidelines, 2010
Figure 2: Prostate Cancer, Global, Sales Value ($m), 2001-2009
Figure 3: Prostate Cancer, Top Seven Countries, Sales Value ($m), 2001-2009
Figure 4: Prostate Cancer Therapeutics Market, Top Seven Countries, Sales Value ($m) by Country, 2001-2009
Figure 5: Prostate Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009
Figure 6: Prostate Cancer Therapeutics Market, Top Seven Countries, Annual Cost of Therapy ($), 2001-2009
Figure 7: Prostate Cancer Therapeutics Market, Global, Patient Volume (’000s), 2001-2009
Figure 8: Prostate Cancer Therapeutics Market, Top Seven Countries , Patient Volume (’000s), 2001-2009
Figure 9: Prostate Cancer Therapeutics Market, Global, Treatment Usage Patterns (’000s), 2001-2009
Figure 10: Prostate Cancer Therapeutics Market, Top Seven Countries, Treatment Usage Patterns (’000s), 2001-2009
Figure 11: Prostate Cancer, Global, Market Drivers and Restraints, 2009
Figure 12: Prostate Cancer Therapeutics Market, Global, Historical Events Impact on the Market, 2010
Figure 13: Prostate Cancer Therapeutics Market, Global, Sales Value ($m), 2009-2020
Figure 14: Prostate Cancer Therapeutics Market, Top Seven Countries, Sales Value ($m), 2009-2020
Figure 15: Prostate Cancer Therapeutics Market, Top Seven Countries, Sales Value ($m) by Country, 2009-2020
Figure 16: Prostate Cancer Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2020
Figure 17: Prostate Cancer Therapeutics Market, Top Seven Countries, Annual Cost of Therapy ($), 2009-2020
Figure 18: Prostate Cancer Therapeutics Market, Global, Patient Volume (’000s), 2009-2020
Figure 19: Prostate Cancer Therapeutics Market, Top Seven Countries, Patient Volume (’000s), 2009-2020
Figure 20: Prostate Cancer Therapeutics Market, Global, Treatment Usage Patterns (’000s), 2009-2020
Figure 21: Prostate Cancer Therapeutics Market, Top Seven Countries, Treatment Usage Patterns (’000s), 2009-2020
Figure 22: Prostate Cancer Therapeutics Market, Global, Future Market Drivers and Restraints, 2009-2020
Figure 23: Prostate Cancer Therapeutics Market, Global, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020
Figure 24: Prostate Cancer Therapeutics Market, Global, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2020
Figure 25: Prostate Cancer Therapeutics Market, Global, Breakdown of Drug Sales (%), 2009
Figure 26: Prostate Cancer Therapeutics Market, US, Sales Value ($m), 2001-2009
Figure 27: Prostate Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2001-2009
Figure 28: Prostate Cancer Therapeutics Market, US, Patient Volume (’000s), 2001-2009
Figure 29: Prostate Cancer Therapeutics Market, US, Treatment Usage Patterns (’000s), 2001-2009
Figure 30: Prostate Cancer Therapeutics Market, US, Market Drivers and Restraints, 2009
Figure 31: Prostate Cancer Therapeutics Market, The US, Historical Events Impact on the Market, 2010
Figure 32: Prostate Cancer Therapeutics Market, US, Sales Value ($m), 2009-2020
Figure 33: Prostate Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2009-2020
Figure 34: Prostate Cancer Therapeutics Market, US, Patient Volume (’000s), 2009-2020
Figure 35: Prostate Cancer Therapeutics Market, US, Treatment Usage Patterns (’000s), 2009-2020
Figure 36: Prostate Cancer Therapeutics Market, The US, Future Market Drivers and Restraints, 2010-2020
Figure 37: Prostate Cancer Therapeutics Market, US, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020
Figure 38: Prostate Cancer Therapeutics Market, US, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2020
Figure 39: Prostate Cancer Therapeutics Market, UK, Sales Value ($m), 2001-2009
Figure 40: Prostate Cancer Therapeutics Market, UK, Annual Cost of Therapy ($), 2001-2009
Figure 41: Prostate Cancer Therapeutics Market, UK, Patient Volume (’000s), 2001-2009
Figure 42: Prostate Cancer Therapeutics Market, UK, Treatment Usage Patterns (’000s), 2001-2009
Figure 43: Prostate Cancer Therapeutics Market, The UK, Market Drivers and Restraints, 2009
Figure 44: Prostate Cancer Therapeutics Market, The UK, Historical Events Impact on the Market, 2010
Figure 45: Prostate Cancer Therapeutics Market, UK, Sales Value ($m), 2009-2020
Figure 46: Prostate Cancer Therapeutics Market, UK, Annual Cost of Therapy ($), 2009-2020
Figure 47: Prostate Cancer Therapeutics Market, UK, Patient Volume (’000s), 2009-2020
Figure 48: Prostate Cancer Therapeutics Market, UK, Treatment Usage Patterns (’000s), 2009-2020
Figure 49: Prostate Cancer Therapeutics Market, The UK, Future Market Drivers and Restraints, 2009-2020
Figure 50: Prostate Cancer Therapeutics Market, UK, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020
Figure 51: Prostate Cancer Therapeutics Market, UK, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2020
Figure 52: Prostate Cancer Therapeutics Market, Germany, Sales Value ($m), 2001-2009
Figure 53: Prostate Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2001-2009
Figure 54: Prostate Cancer Therapeutics Market, Germany, Patient Volume (’000s), 2001-2009
Figure 55: Prostate Cancer Therapeutics Market, Germany, Treatment Usage Patterns (’000s), 2001-2009
Figure 56: Prostate Cancer Therapeutics Market, Germany, Market Drivers and Restraints, 2009
Figure 57: Prostate Cancer Therapeutics Market, Germany, Historical Events Impact on the Market, 2010
Figure 58: Prostate Cancer Therapeutics Market, Germany, Sales Value ($m), 2009-2020
Figure 59: Prostate Cancer Therapeutics Market, Germany, Annual Cost of Therapy ($), 2009-2020
Figure 60: Prostate Cancer Therapeutics Market, Germany, Patient Volume (’000s), 2009-2020
Figure 61: Prostate Cancer Therapeutics Market, Germany, Treatment Usage Patterns (’000s), 2009-2020
Figure 62: Prostate Cancer Therapeutics Market, Germany, Future Market Drivers and Restraints, 2009-2020
Figure 63: Prostate Cancer Therapeutics Market, Germany, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020
Figure 64: Prostate Cancer Therapeutics Market, Germany, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2020
Figure 65: Prostate Cancer Therapeutics Market, France, Sales Value ($m), 2001-2009
Figure 66: Prostate Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2001-2009
Figure 67: Prostate Cancer Therapeutics Market, France, Patient Volume (’000s), 2001-2009
Figure 68: Prostate Cancer Therapeutics Market, France, Treatment Usage Patterns (’000s), 2001-2009
Figure 69: Prostate Cancer, France, Market Drivers and Restraints, 2009
Figure 70: Prostate Cancer, France, Historical Events Impact on the Market, 2010
Figure 71: Prostate Cancer Therapeutics Market, France, Sales Value ($m), 2009-2020
Figure 72: Prostate Cancer Therapeutics Market, France, Annual Cost of Therapy ($), 2009-2020
Figure 73: Prostate Cancer Therapeutics Market, France, Patient Volume (’000s), 2009-2020
Figure 74: Prostate Cancer Therapeutics Market, France, Treatment Usage Patterns (’000s), 2009-2020
Figure 75: Prostate Cancer Therapeutics Market, France, Future Market Drivers and Restraints, 2009-2020
Figure 76: Prostate Cancer Therapeutics Market, France, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020
Figure 77: Prostate Cancer Therapeutics Market, France, Hormone-dependent Prostate Cancer Drug Sales ($m), 2001-2020
Figure 78: Prostate Cancer Therapeutics Market, Italy, Sales Value ($m), 2001-2009
Figure 79: Prostate Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2001-2009
Figure 80: Prostate Cancer Therapeutics Market, Italy, Patient Volume (’000s), 2001-2009
Figure 81: Prostate Cancer Therapeutics Market, Italy, Treatment Usage Patterns (’000s), 2001-2009
Figure 82: Prostate Cancer Therapeutics Market, Italy, Market Drivers and Restraints, 2009
Figure 83: Prostate Cancer Therapeutics Market, Italy, Historical Events Impact on the Market, 2010
Figure 84: Prostate Cancer Therapeutics Market, Italy, Sales Value ($m), 2009-2020
Figure 85: Prostate Cancer Therapeutics Market, Italy, Annual Cost of Therapy ($), 2009-2020
Figure 86: Prostate Cancer Therapeutics Market, Italy, Patient Volume (’000s), 2009-2020
Figure 87: Prostate Cancer Therapeutics Market, Italy, Treatment Usage Patterns (’000s), 2009-2020
Figure 88: Prostate Cancer Therapeutics Market, Italy, Future Market Drivers and Restraints, 2009-2020
Figure 89: Prostate Cancer Therapeutics Market, Italy, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020
Figure 90: Prostate Cancer Therapeutics Market, Italy, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2001-2020
Figure 91: Prostate Cancer Therapeutics Market, Spain, Sales Value ($m), 2001-2009
Figure 92: Prostate Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2001-2009
Figure 93: Prostate Cancer Therapeutics Market, Spain, Patient Volume (’000s), 2001-2009
Figure 94: Prostate Cancer Therapeutics Market, Spain, Treatment Usage Patterns (’000s), 2001-2009
Figure 95: Prostate Cancer Therapeutics Market, Spain, Market Drivers and Restraints, 2009
Figure 96: Prostate Cancer Therapeutics Market, Spain, Historical Events Impact on the Market, 2010
Figure 97: Prostate Cancer Therapeutics Market, Spain, Sales Value ($m), 2009-2020
Figure 98: Prostate Cancer Therapeutics Market, Spain, Annual Cost of Therapy ($), 2009-2020
Figure 99: Prostate Cancer Therapeutics Market, Spain, Patient Volume (’000s), 2009-2020
Figure 100: Prostate Cancer Therapeutics Market, Spain, Treatment Usage Patterns (’000s), 2009-2020
Figure 101: Prostate Cancer Therapeutics Market, Spain, Future Market Drivers and Restraints, 2009-2020
Figure 102: Prostate Cancer Therapeutics Market, Spain, Hormone-refractory Prostate Cancer Drug Sales ($m), 2001-2020
Figure 103: Prostate Cancer Therapeutics Market, Spain, Hormone-Dependent Prostate Cancer Drug Sales ($m), 2001-2020
Figure 104: Prostate Cancer Therapeutics Market, Japan, Sales Value ($m), 2001-2009
Figure 105: Prostate Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2001-2009
Figure 106: Prostate Cancer Therapeutics Market, Japan, Patient Volume (’000s), 2001-2009
Figure 107: Prostate Cancer Therapeutics Market, Japan, Treatment Usage Patterns (’000s), 2001-2009
Figure 108: Prostate Cancer Therapeutics Market, Japan, Market Driv